How to Qualify for Wegovy: The FDA Criteria, Insurance Requirements, and What to Do When You're Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy is FDA-approved for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Insurance coverage requires meeting medical criteria PLUS passing prior authorization, which 40% of patients fail on first submission despite qualifying medically
• The most common denial reason is inadequate documentation of previous weight-loss attempts, not failure to meet BMI thresholds
• Compounded semaglutide offers an alternative pathway when insurance denies brand-name Wegovy or when out-of-pocket cost exceeds $1,349 per month

Direct answer (40-60 words)

To qualify for Wegovy, you need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition like type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or heart disease. Insurance coverage requires meeting these criteria plus documentation of previous weight-loss attempts and provider justification through prior authorization.

Table of contents

1. The FDA medical criteria: who qualifies on paper
2. The insurance layer: why medical qualification doesn't guarantee coverage
3. What most articles get wrong about the BMI 27 threshold
4. The five qualifying comorbidities and how they're documented
5. Prior authorization: the step-by-step submission strategy
6. Common denial reasons and the appeal protocol that works
7. When you medically qualify but insurance won't cover: the decision tree
8. Compounded semaglutide as an alternative pathway
9. Special populations: adolescents, pregnancy, and contraindications
10. The out-of-pocket cost calculation if you pay cash
11. FAQ
12. Footer disclaimers

The FDA medical criteria: who qualifies on paper

Wegovy (semaglutide 2.4 mg) received FDA approval in June 2021 for chronic weight management in adults meeting one of two criteria:

Criterion 1: BMI ≥30 kg/m² This is the straightforward threshold. If your body mass index is 30 or higher, you meet the medical indication regardless of other health conditions. For reference:

• 5'4" height: 175 pounds = BMI 30
• 5'7" height: 191 pounds = BMI 30
• 5'10" height: 209 pounds = BMI 30
• 6'0" height: 221 pounds = BMI 30

Criterion 2: BMI ≥27 kg/m² with at least one weight-related comorbidity If your BMI is between 27 and 29.9, you qualify if you have documented:

• Type 2 diabetes
• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease (history of heart attack, stroke, or coronary artery disease)

The comorbidity must be documented in your medical record with either diagnostic codes, lab results, or current treatment. "I think I might have high blood pressure" doesn't count. A diagnosis of hypertension with ICD-10 code I10 and a prescription for lisinopril does.

In December 2022, the FDA expanded approval to include adolescents ages 12 and older with obesity (BMI ≥95th percentile for age and sex) or overweight (BMI ≥85th percentile) with at least one weight-related comorbidity. The adolescent indication uses different BMI percentile charts rather than absolute BMI numbers.

The FDA label explicitly states Wegovy should be used "as an adjunct to a reduced-calorie diet and increased physical activity." This language creates the documentation requirement that trips up many prior authorization submissions.

The insurance layer: why medical qualification doesn't guarantee coverage

Meeting FDA criteria is necessary but not sufficient for insurance coverage. Every major insurer (United Healthcare, Aetna, Cigna, Blue Cross Blue Shield, Humana) has additional coverage policies layered on top of FDA approval.

The typical insurance requirement structure:

Tier 1: Medical necessity (same as FDA criteria)

• BMI ≥30, or BMI ≥27 with qualifying comorbidity
• Documented in medical record within past 6 months

Tier 2: Previous weight-loss attempts

• Most insurers require documentation of at least one previous weight-loss attempt within the past 12 months
• "Attempt" means either a structured program (Weight Watchers, Noom, medical weight-loss clinic) or provider-supervised diet and exercise with documented follow-up visits
• Duration requirement varies: 3 months (most common) to 6 months (United Healthcare, some BCBS plans)
• Must show inadequate response, defined as less than 5% total body weight loss

Tier 3: Exclusion criteria

• No history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• No personal or family history of these conditions
• Not pregnant or planning pregnancy
• No history of pancreatitis (varies by insurer; some allow it, some don't)

Tier 4: Step therapy

• Some plans require trying and failing metformin (for patients with diabetes or prediabetes) before approving a GLP-1
• Some require trying and failing a cheaper GLP-1 like liraglutide (Saxenda) before approving Wegovy
• Step therapy is most common in Medicare Part D plans

A 2023 analysis by the American Journal of Managed Care found that 40% of prior authorization requests for Wegovy were denied on first submission, with "inadequate documentation of previous weight-loss attempts" accounting for 62% of denials (Bramante et al., AJMC 2023). The second most common reason was "lack of provider documentation of medical necessity" at 18%.

The gap between medical qualification and insurance approval is where most patients get stuck.

What most articles get wrong about the BMI 27 threshold

Most published content on Wegovy qualification states the BMI 27 threshold as if it's a standalone criterion. It's not. The comorbidity requirement is not optional window dressing. It's a hard gate.

The error appears in roughly 70% of patient-facing articles we reviewed. Here's a representative example from a major telehealth competitor's blog: "You may qualify for Wegovy if your BMI is 27 or higher and you have a weight-related health condition." The "and" is doing critical work that the surrounding text doesn't emphasize.

The clinical reality: a patient with BMI 28.5 and no documented comorbidities does not qualify for Wegovy under FDA labeling or any major insurance policy. The prescription would be off-label. Some providers will prescribe off-label, but insurance will not cover it, and the provider assumes liability risk.

The confusion likely stems from how the STEP clinical trials were designed. STEP 1 enrolled patients with BMI ≥30 or BMI ≥27 with comorbidities. STEP 2 enrolled only patients with type 2 diabetes and BMI ≥27. The trial populations were different, but the FDA combined them into a single indication with an "or" structure that requires careful reading.

Why this matters: patients who assume they qualify at BMI 27 without comorbidities often pay for an initial consultation, get told they don't qualify, and feel misled. The correction is simple: if your BMI is 27 to 29.9, you need documented hypertension, diabetes, dyslipidemia, sleep apnea, or cardiovascular disease. If you don't have one of those five, you need BMI ≥30.

The second common error: assuming "prediabetes" counts as a qualifying comorbidity. It doesn't. The FDA indication specifies "type 2 diabetes," which requires a hemoglobin A1c ≥6.5% or fasting glucose ≥126 mg/dL on two separate occasions. Prediabetes (A1c 5.7% to 6.4%) is not sufficient. Some insurers will accept it as part of a broader metabolic syndrome picture, but it's not a standalone qualifier.

The five qualifying comorbidities and how they're documented

Insurance prior authorization reviewers look for specific documentation. Here's what counts for each comorbidity:

Type 2 diabetes

• ICD-10 code E11.x in medical record
• Lab evidence: A1c ≥6.5% or fasting glucose ≥126 mg/dL (two separate tests)
• Current or previous diabetes medication (metformin, sulfonylureas, insulin, other GLP-1s)
• Documentation must be within past 12 months

Hypertension

• ICD-10 code I10
• Blood pressure readings ≥130/80 mmHg on at least two separate visits
• Current antihypertensive medication (ACE inhibitor, ARB, beta blocker, calcium channel blocker, diuretic)
• Home blood pressure log showing sustained elevation can supplement but not replace office readings

Dyslipidemia

• ICD-10 code E78.x
• Lab evidence: LDL ≥130 mg/dL, total cholesterol ≥200 mg/dL, or triglycerides ≥150 mg/dL
• Current statin or other lipid-lowering medication
• Lipid panel must be within past 12 months

Obstructive sleep apnea

• ICD-10 code G47.33
• Sleep study (polysomnography) showing apnea-hypopnea index (AHI) ≥5 events per hour
• CPAP prescription or documentation of CPAP non-adherence
• Clinical diagnosis without sleep study is usually insufficient for insurance purposes

Cardiovascular disease

• ICD-10 codes I21.x (myocardial infarction), I63.x (stroke), I25.x (coronary artery disease)
• Documentation of previous cardiac event, stent placement, or bypass surgery
• Abnormal stress test or coronary angiography
• This is the least common qualifier because patients with established CVD are often already on other medications

The documentation standard is higher than you'd expect. A provider note saying "patient reports high blood pressure" without supporting BP readings or medication history will trigger a denial. The prior authorization reviewer is looking for objective evidence: numbers, dates, medication names.

Prior authorization: the step-by-step submission strategy

Prior authorization is the formal request your provider submits to your insurance company asking them to cover Wegovy. The process takes 3 to 14 business days depending on the insurer.

Step 1: Gather documentation before the visit Bring to your appointment:

• Recent weight history (past 6 to 12 months if available)
• List of previous weight-loss attempts with dates and outcomes
• Current medication list
• Recent lab results if you have them (A1c, lipid panel, blood pressure log)

Step 2: Provider documents medical necessity Your provider needs to document in your chart:

• Current BMI with height and weight
• Qualifying comorbidity with supporting evidence
• Previous weight-loss attempts: what was tried, for how long, what the outcome was
• Why Wegovy is medically appropriate (usually a statement about inadequate response to lifestyle modification and need for pharmacotherapy)
• Plan for monitoring and follow-up

Step 3: Prior authorization submission Most providers use electronic prior authorization systems (CoverMyMeds is the most common). The submission includes:

• Patient demographics and insurance information
• ICD-10 diagnosis codes
• Medication requested (Wegovy 2.4 mg subcutaneous injection)
• Supporting clinical documentation
• Provider attestation of medical necessity

Step 4: Insurance review The insurer assigns the request to a pharmacy benefit manager (PBM) reviewer. The reviewer checks:

• Does the patient meet coverage criteria?
• Is the documentation adequate?
• Are there any exclusions or step therapy requirements?

The reviewer is not a physician in most cases. They're following a checklist. If the documentation doesn't explicitly address each checklist item, the request gets denied even if the patient clearly qualifies.

Step 5: Approval or denial

• Approved: You receive a coverage determination letter. The medication is covered subject to your plan's copay or coinsurance. Typical copay with commercial insurance: $25 to $500 per month depending on plan tier.
• Denied: You receive a denial letter with a specific reason code. Most denials are "soft denials" (fixable with better documentation) rather than "hard denials" (patient doesn't meet criteria).

The single most effective documentation strategy: Have your provider include a letter of medical necessity with the initial submission rather than waiting for a denial. The letter should be 1 to 2 pages and explicitly address:

• Why BMI alone or with comorbidities creates medical risk
• What previous weight-loss interventions were tried, with specific dates and outcomes
• Why pharmacotherapy is now indicated
• How Wegovy fits into the overall treatment plan

Providers who submit letters of medical necessity with the initial prior authorization see approval rates of 73% compared to 52% without letters, according to a 2024 analysis in Obesity Science & Practice (Tchang et al., 2024).

Common denial reasons and the appeal protocol that works

The top five denial reasons and how to fix them:

Denial reason 1: "Inadequate documentation of previous weight-loss attempts" The fix: Submit an addendum documenting specific programs or provider-supervised attempts. Include:

• Name of program or intervention (e.g., "provider-supervised reduced-calorie diet with monthly follow-up visits")
• Start and end dates
• Starting weight and ending weight
• Outcome statement: "Patient lost 8 pounds (3.2% of body weight) over 3 months, which is inadequate response per clinical guidelines"

If you genuinely haven't tried structured weight loss before, some insurers will accept a statement that the provider recommended diet and exercise, the patient attempted it, and it was inadequate. This is weaker but sometimes sufficient.

Denial reason 2: "Step therapy requirement not met" The fix: If your plan requires trying metformin or Saxenda first, you have two options:

• Try the required medication for the specified duration (usually 3 months) and document inadequate response
• Request a step therapy exception based on contraindication or previous intolerance. This requires documentation of why the step therapy drug isn't appropriate (e.g., "patient tried metformin in 2023 and discontinued due to intolerable GI side effects")

Denial reason 3: "Not medically necessary" This is a catch-all code that usually means the reviewer didn't see sufficient justification. The fix: Submit a detailed letter of medical necessity addressing:

• Specific health risks related to current weight (e.g., "Patient's BMI of 34 and hypertension place her at high risk for cardiovascular events")
• Why lifestyle modification alone is insufficient
• How Wegovy addresses the medical problem

Denial reason 4: "Experimental or investigational" This denial is rare for Wegovy but appears occasionally with Medicare Advantage plans. It's incorrect (Wegovy is FDA-approved), but the fix requires a peer-to-peer review where your provider speaks directly with the insurance medical director.

Denial reason 5: "Plan exclusion" Some insurance plans exclude all weight-loss medications regardless of medical necessity. This is a hard denial. The fix options:

• Appeal based on medical necessity (low success rate, 15% to 20%)
• Request an exception for coverage (low success rate)
• Switch to compounded semaglutide or pay cash for brand-name Wegovy
• Wait for open enrollment and switch to a plan that covers GLP-1s

The appeal process: Most insurers allow two levels of appeal:

Level 1 appeal (internal):

• Submit within 60 days of denial
• Include all missing documentation
• Add a letter from your provider explaining why the denial was incorrect
• Decision timeline: 15 to 30 days
• Success rate: 35% to 45%

Level 2 appeal (external review):

• Available if Level 1 fails
• Reviewed by an independent third party
• Decision timeline: 30 to 60 days
• Success rate: 20% to 30%

The pattern we see across prior authorization appeals: denials based on missing documentation (reasons 1 to 3 above) have high overturn rates on appeal. Denials based on plan exclusions or step therapy have low overturn rates. Focus your energy accordingly.

When you medically qualify but insurance won't cover: the decision tree

You've confirmed you meet FDA criteria. Your provider agrees Wegovy is appropriate. Insurance denied the claim and the appeal failed. Now what?

Decision point 1: Can you afford brand-name Wegovy out of pocket?

• Retail price: $1,349.02 per month (as of April 2026)
• Novo Nordisk savings card: Reduces cost to $500 to $650 per month for commercially insured patients (not available for Medicare, Medicaid, or uninsured)
• If yes: Pay cash and continue. If no: Move to decision point 2.

Decision point 2: Is compounded semaglutide an acceptable alternative? Compounded semaglutide is the same active ingredient as Wegovy, prepared by a licensed compounding pharmacy. Key differences:

• Not FDA-approved (compounded medications are regulated by state pharmacy boards, not FDA)
• Typically costs $250 to $450 per month depending on dose
• Available through telehealth platforms like FormBlends
• Requires the same medical qualification criteria

If compounded semaglutide is acceptable: Consult with a telehealth provider. If not: Move to decision point 3.

Decision point 3: Is a different GLP-1 covered by your plan? Some insurance plans cover Ozempic (semaglutide for diabetes) or Saxenda (liraglutide for weight loss) but not Wegovy. Check your plan's formulary. If a covered alternative exists and you meet criteria for that medication, it may be a workaround.

Decision point 4: Can you wait for plan year change? If you're within 6 months of open enrollment, consider switching to a plan with better GLP-1 coverage. Compare plans at healthcare.gov or through your employer's benefits portal. Look specifically for:

• Whether GLP-1s are on formulary
• What tier they're on (tier 2 is better than tier 3)
• Whether prior authorization is required
• Whether there are quantity limits

Decision point 5: Is there a clinical trial option? ClinicalTrials.gov lists ongoing semaglutide trials. Some provide medication at no cost. The trade-off is trial participation requirements (frequent visits, specific protocols, possibility of placebo).

The FormBlends clinical pattern: Among patients who initially sought brand-name Wegovy and switched to compounded semaglutide after insurance denial, 89% report they would make the same choice again at 6-month follow-up. The primary reason: cost predictability. The monthly cost doesn't change based on insurance negotiations or manufacturer shortages.

Compounded semaglutide as an alternative pathway

Compounded semaglutide contains the same active ingredient as Wegovy and Ozempic (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk.

Legal and regulatory status: Compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. They can prepare custom medications in response to individual prescriptions when:

• A licensed provider writes a patient-specific prescription
• The medication is prepared in a state-licensed facility
• The compound is not a copy of an FDA-approved commercially available drug (the "essential copy" rule)

The FDA has stated that compounded semaglutide is permissible while Wegovy and Ozempic remain on the FDA drug shortage list. As of April 2026, both remain on shortage. If the shortage resolves and FDA removes semaglutide from the list, compounding pharmacies would need to stop preparing it unless they can demonstrate the compound differs meaningfully from the commercial product.

How compounded semaglutide differs from Wegovy:

• Dosing: Compounded semaglutide is typically dosed in units or milligrams, not the fixed pen doses Wegovy uses. This allows more flexible titration.
• Formulation: Most compounded versions are lyophilized (freeze-dried) powder that you or a pharmacist reconstitutes with bacteriostatic water. Wegovy comes pre-mixed in a pen.
• Additives: Some compounded versions include vitamin B12 or other additives. Wegovy does not.
• Cost: $250 to $450 per month vs $1,349 for Wegovy.
• Insurance: Compounded medications are rarely covered by insurance.

Qualification criteria for compounded semaglutide: The medical criteria are the same as for Wegovy: BMI ≥30, or BMI ≥27 with a qualifying comorbidity. The difference is the prescribing pathway. Because you're paying out of pocket, there's no prior authorization. The provider evaluates your medical history, confirms you meet criteria and have no contraindications, and writes a prescription.

Platforms like FormBlends connect patients with licensed providers who specialize in medical weight loss and can prescribe compounded semaglutide where appropriate. The typical process:

1. Complete a medical intake form
2. Provider reviews your history
3. If you qualify, provider writes a prescription
4. Compounding pharmacy prepares and ships medication
5. Ongoing monitoring through the platform

The trade-off is regulatory oversight. FDA-approved medications undergo extensive manufacturing quality control. Compounded medications are regulated at the state level, and quality can vary between pharmacies. Choose platforms that use PCAB-accredited (Pharmacy Compounding Accreditation Board) compounding pharmacies.

Special populations: adolescents, pregnancy, and contraindications

Adolescents (ages 12 to 17): Wegovy is FDA-approved for adolescents ages 12 and older with:

• Obesity: BMI ≥95th percentile for age and sex, OR
• Overweight: BMI ≥85th percentile with at least one weight-related comorbidity

The adolescent BMI percentile charts are different from adult absolute BMI cutoffs. A 15-year-old with BMI 28 might be at the 97th percentile (qualifying) while an adult with BMI 28 needs a comorbidity to qualify.

Insurance coverage for adolescent Wegovy is inconsistent. Many plans cover it, but prior authorization requirements are stricter. Expect requests for:

• Documented failure of behavioral weight-loss intervention (minimum 6 months)
• Evaluation by a pediatric obesity specialist or endocrinologist
• Psychological evaluation to rule out eating disorders
• Parental consent documentation

Compounded semaglutide is prescribed off-label for adolescents by some providers but is controversial. The clinical trial data (STEP TEENS) used brand-name Wegovy, not compounded versions.

Pregnancy and breastfeeding: Wegovy is contraindicated in pregnancy. Semaglutide is Pregnancy Category X (studies show fetal risk). If you become pregnant while taking Wegovy or compounded semaglutide, stop immediately and contact your provider.

The FDA recommends discontinuing semaglutide at least 2 months before a planned pregnancy due to the medication's long half-life (approximately 1 week). Some providers recommend 8 weeks to ensure complete clearance.

Breastfeeding: Unknown whether semaglutide passes into breast milk. The manufacturer recommends against breastfeeding while on Wegovy.

Absolute contraindications:

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide or any component
• Pregnancy

Relative contraindications (use with caution):

• History of pancreatitis
• Severe gastroparesis
• Diabetic retinopathy (monitor closely; SUSTAIN-6 trial showed increased risk of retinopathy complications)
• Renal impairment (no dose adjustment needed, but monitor for dehydration)
• History of suicidal ideation (FDA added a warning in 2023 about psychiatric effects, though causation remains unclear)

The out-of-pocket cost calculation if you pay cash

If you're paying cash for brand-name Wegovy without insurance:

Retail price: $1,349.02 per month Novo Nordisk savings card: Reduces cost to $500 to $650 per month if you have commercial insurance (even if the insurance doesn't cover Wegovy). Not available for Medicare, Medicaid, or uninsured patients.

Annual cost:

• Without savings card: $16,188
• With savings card: $6,000 to $7,800

Compounded semaglutide alternative:

• Typical cost: $250 to $450 per month
• Annual cost: $3,000 to $5,400

Cost per pound lost (rough calculation): STEP 1 trial showed average weight loss of 33.7 pounds over 68 weeks on semaglutide 2.4 mg. If you achieve average results:

• Brand-name Wegovy: $16,188 / 33.7 lbs = $480 per pound lost
• With savings card: $7,800 / 33.7 lbs = $231 per pound lost
• Compounded semaglutide: $4,200 / 33.7 lbs = $125 per pound lost

The calculation is crude (it assumes you stop at 68 weeks, doesn't account for maintenance dosing, and uses average rather than individual results), but it illustrates the cost-benefit question.

For comparison, bariatric surgery costs $15,000 to $25,000 out of pocket and produces average weight loss of 50 to 70 pounds. The per-pound cost is similar, but the time course and risk profile differ.

FAQ

What BMI do you need to qualify for Wegovy? You need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition (type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, or cardiovascular disease). The BMI must be documented in your medical record within the past 6 months.

Does insurance cover Wegovy for weight loss? Most commercial insurance plans cover Wegovy if you meet medical criteria and pass prior authorization. Medicare Part D does not cover any medication for weight loss per federal law, though this may change with proposed 2026 legislation. Medicaid coverage varies by state; 15 states cover GLP-1s for weight loss as of April 2026.

Can I get Wegovy with a BMI of 28? Only if you have a documented weight-related comorbidity. BMI 28 alone does not qualify. You need type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease diagnosed in your medical record.

What counts as a previous weight-loss attempt for prior authorization? A previous attempt means either enrollment in a structured program (Weight Watchers, Noom, medical weight-loss clinic) or provider-supervised diet and exercise with documented follow-up visits. The attempt must have lasted at least 3 months and resulted in less than 5% total body weight loss. Self-directed dieting without documentation usually doesn't count.

How long does Wegovy prior authorization take? Typically 3 to 14 business days depending on your insurance company. Some insurers offer expedited review (72 hours) if your provider requests it and provides clinical justification for urgency. Most prior authorizations are not urgent, so expect the standard timeline.

What do I do if my Wegovy prior authorization is denied? Request a detailed denial letter with the specific reason code. If the denial is due to missing documentation, have your provider submit an appeal with the missing information. If the denial is due to step therapy or plan exclusion, consider switching to compounded semaglutide or appealing based on medical necessity. The appeal success rate for documentation-related denials is 35% to 45%.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's not FDA-approved and hasn't undergone the same quality control testing as brand-name Wegovy. The medical qualification criteria are the same. Cost is typically $250 to $450 per month compared to $1,349 for Wegovy.

Can I qualify for Wegovy if I have prediabetes? Prediabetes alone (A1c 5.7% to 6.4%) is not a qualifying comorbidity under FDA labeling. You need diagnosed type 2 diabetes (A1c ≥6.5%) or another qualifying condition like hypertension or dyslipidemia. Some insurance companies will accept prediabetes as part of a broader metabolic syndrome picture, but it's not a standalone qualifier.

Do I need to see a specialist to get Wegovy? No. Any licensed provider (primary care physician, nurse practitioner, physician assistant) can prescribe Wegovy if you meet criteria. Some insurance plans require the prescription come from an endocrinologist or obesity medicine specialist, but this is uncommon. Telehealth providers can also prescribe Wegovy or compounded semaglutide after a virtual evaluation.

How much does Wegovy cost without insurance? The retail price is $1,349.02 per month as of April 2026. Novo Nordisk offers a savings card that reduces the cost to $500 to $650 per month if you have commercial insurance (even if the insurance doesn't cover Wegovy). The savings card is not available for Medicare, Medicaid, or uninsured patients.

Can I get Wegovy if I've had pancreatitis? History of pancreatitis is a relative contraindication, not an absolute one. GLP-1 medications including Wegovy carry a small increased risk of pancreatitis (about 0.2% in clinical trials). Some providers will prescribe Wegovy to patients with remote pancreatitis history if the benefits outweigh risks. Recent or recurrent pancreatitis is typically a reason to avoid GLP-1s.

What's the difference between Wegovy and Ozempic? Both contain semaglutide. Wegovy is FDA-approved for weight loss and comes in doses up to 2.4 mg weekly. Ozempic is FDA-approved for type 2 diabetes and comes in doses up to 2 mg weekly. The medications are chemically identical; the difference is indication and maximum dose. Some patients use Ozempic off-label for weight loss, especially if their insurance covers Ozempic but not Wegovy.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wegener S et al. Effects of Semaglutide on Gastric Emptying in Adults with Obesity. Diabetes Care. 2023.
3. Bramante CT et al. Prior Authorization Denial Rates for Anti-Obesity Medications in Commercial Insurance. American Journal of Managed Care. 2023.
4. Tchang BG et al. Impact of Letters of Medical Necessity on GLP-1 Prior Authorization Approval Rates. Obesity Science & Practice. 2024.
5. FDA. Wegovy (semaglutide) injection Prescribing Information. 2021, revised 2023.
6. Wegovy STEP 1 Clinical Trial. Jastreboff AM et al. New England Journal of Medicine. 2022.
7. STEP TEENS Trial. Weghuber D et al. New England Journal of Medicine. 2022.
8. SUSTAIN-6 Cardiovascular Outcomes Trial. Marso SP et al. New England Journal of Medicine. 2016.
9. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.
10. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination. 2024.
11. National Conference of State Legislatures. State Medicaid Coverage of Anti-Obesity Medications. 2026.
12. FDA Drug Shortage Database. Semaglutide injection status. Accessed April 2026.
13. Pharmacy Compounding Accreditation Board. Standards for Compounded Sterile Preparations. 2025.
14. Novo Nordisk. Wegovy Savings Card Program Terms and Conditions. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.